Bionano projects full-year 2025 revenues to be in the range of $29 million to $32 million, supported by its strategic focus on routine users. First-quarter 2025 revenues are expected to range from ...

Bionano Genomics Inc. (NASDAQ:BNGO) stock has tumbled to a 52-week low, touching down at $0.17, as the company faces a turbulent market environment. With a market capitalization of just $18.92 ...

Bionano Genomics (NASDAQ:BNGO) is preparing to release its quarterly earnings on Wednesday, 2025-05-14. Here's a brief overview of what investors should keep in mind before the announcement.

The story underpinning Bionano Genomics (NASDAQ:BNGO) stock unquestionably is intriguing. Bionano claims to offer a substantial improvement in genome analysis that enables more patients to be ...

Those who held BioNano Genomics (NASDAQ:BNGO) stock from late December until mid-February had a very happy start to 2021. Source: Connect world / S hutterstock.com BNGO stock rocketed from 51 ...

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...

Bionano Genomics stock has had a rough 12 months. But its business model is still attractive due to its long-term recurring revenue potential. Developing new consumables and new devices will also ...

Should this divergence continue over the coming 3-5 years, investments in Bionano and many other genomics stocks may continue to prosper. Data by YCharts. The risks to the bull thesis.

SAN DIEGO, April 17, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ...

Shares of Bionano Genomics Inc. gained 10.3% in premarket trading on Friday following a week of heavy trading on the stock. The company's stock price has tripled since the start of the year ...